Maravai LifeSciences Reports First Quarter 2026 Financial Results
Maravai LifeSciences reported Q1 revenue of $65.8 million, up 41% year-over-year, driven by a 65% surge in TriLink revenue. The company returned to positive free cash flow with $4.2 million generated and posted Adjusted EBITDA of $20.3 million, compared to a loss in the prior year.
Key figures
- Revenue
- $65.8 million
- Guidance
- FY26 revenue $205.0M-$215.0M (raised from $200.0M-$210.0M); Adjusted EBITDA $30.0M-$32.0M (raised from $18.0M-$20.0M)
- Revenue Yoy
- 41%
- Cygnus revenue
- $18.4 million
- Free cash flow
- $4.2 million
- Adjusted ebitda
- $20.3 million
- Trilink revenue
- $47.5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.